Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
Jan 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme announces early access program
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S - CORRECTION
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Notice to convene EGM correction
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Read moreOrphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces 12-month interim data from an open-label extension of a phase 2/3 study of arimoclomol, an investigational product candidate in development for Niemann-Pick disease Type C (NPC).
Orphazyme reports positive arimoclomol data
Read moreMajor shareholder announcement
Dec 19, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of December 18, 2019 holds a total 991,557 shares in the Company, corresponding to 4.96% of the share capital and that Danske Bank as of December 18, 2019 controls 7.42% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
Dec 18, 2019
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today received Fast Track designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM).
Orphazyme s arimoclomol receives us fast track ...
Read moreMajor shareholder announcement
Nov 28, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of November 27, 2019 holds a total 999,606 shares in the Company, corresponding to 5.00% of the share capital and that Danske Bank as of November 27, 2019 controls 7.53% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
Nov 19, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclomol, an investigational drug for the treatment of Niemann-Pick Disease Type C (NPC).
Orphazyme receives breakthrough therapy designation
Read moreFinancial calendar 2020
Nov 1, 2019
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule.
Read moreMajor shareholder announcement
Oct 2, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of October 1, 2019 holds a total 998,962 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of October 1, 2019 controls 7.74% of the voting rights in the Company.
Major shareholder announcement
Read more